Cardio-vascular
Refine Search
Biotechnology
German life sciences group Bayer was up more than 2% as Wednesday’s trading day neared its end, after the company presented its third-quarter financial results. 30 October 2019
Pharmaceutical
The share price of Pfizer was up 3% at lunchtime on Tuesday after the world’s biggest pharma company presented its third quarter financial results. 29 October 2019
Pharmaceutical
Independent French drugmaker Servier plans to accelerate its expansion both in the domestic market and abroad within the next several years, that will mainly take place through the expansion of the already existing range and the launch of production of new drugs. 29 October 2019
Generics
Czech drugmaker Zentiva has announced it will buy the Central and Eastern European business of Alvogen, for an undisclosed amount. 25 October 2019
Biotechnology
US biotech Amgen has said that, from December 31, 2019, its PCSK9 inhibitor Repatha (evolocumab) will be available exclusively at its lower list price in the USA. 24 October 2019
Pharmaceutical
Shares in Anglo-Swedish pharma major AstraZeneca were up 3% by lunchtime on Thursday, taking the company’s stock market gains for the year-to-date beyond 20%. 24 October 2019
Pharmaceutical
British drugmaker AstraZeneca has won US Food and Drug Administration approval for a new indication for the first-in-class SGLT2 blocker Farxiga (dapagliflozin). 21 October 2019
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) yesterday released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and long-term value for money of Janssen Pharmaceuticals’ Xarelto (rivaroxaban) and Vascepa (icosapent ethyl) from Amarin Pharma =as additive treatments for cardiovascular disease (CVD). 18 October 2019
Generics
The US Food and Drug Administration has posted a warning letter to Indian drugmaker Torrent Pharmaceuticals. 16 October 2019
Generics
Russian drugmakers are considering more active foreign expansion that will be in the form of larger exports of their products, according to recent statements of producers and industry analysts, reports The Pharma Letter’s local correspondent. 15 October 2019
Pharmaceutical
Japan's Daiichi Sankyo has bought an antiemetic and two anti-hypertensive products from fellow Tokyo-based firm Astellas Pharma. 15 October 2019
Pharmaceutical
The European subsidiary of Japan’s Daiichi Sankyo (TYO: 4568) today announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly, treated with its already-marketed Lixiana (edoxaban). 14 October 2019
Pharmaceutical
Last week’s deal-making news included Akcea Therapeutics and majority owner Ionis Pharmaceuticals joining forces with US pharma giant Pfizer on cardiovascular and metabolic diseases research. Also, bluebird bio entered into a gene editing deal with Denmark’s Novo Nordisk to tackle hemophilia A. Regulatory news included Swiss giant Novartis announcing that its much-anticipated anti-VEGF treatment Beovu (brolucizumab) for wet age-related macular degeneration had received approval from the Food and Drug Administration. On the M&A front, investors applauded on Thursday when US biotech Ra Pharma agreed to a $2.1 billion takeover offer from Belgium’s UCB. 13 October 2019
Pharmaceutical
Kitov Pharmaceuticals today announced its combination drug to treat osteoarthritis pain and hypertension is expected to be commercially available in the USA within the fourth quarter of 2019. 11 October 2019
Pharmaceutical
Despite new launches dropping abysmally, India’s pharmaceutical market has grown at its fastest pace in more than a year in the quarter ended September given higher volumes and prices. According to data from market research agency AIOCD-AWACS, the Indian pharma market expanded 11.5% for the quarter ended September 30. 10 October 2019
Biotechnology
Shares of Akcea Therapeutics, a majority-owned affiliate of Ionis Pharmaceuticals, leapt 22.3% to $18.50 in pre-market trading today, after the companies revealed a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with US pharma giant Pfizer 7 October 2019
Biotechnology
California, USA-based discovery start-up Tenaya Therapeutics today announced the successful completion of a $92 million Series B financing. 3 October 2019
Pharmaceutical
The US Food and Drug Administration has approved a new indication for Invokana (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine 1 October 2019
Pharmaceutical
With nitrosamines impurities now identified in ranitidine and ‘sartan’ medicines, the European Medicines Agency’s human medicines committee (CHMP) is requesting as a matter of precaution that marketing authorization holders for human medicines containing chemically synthesised active substances review their medicines for the possible presence of nitrosamines and test all products at risk. 26 September 2019
Biotechnology
US Venture capital-backed biotech Blade Therapeutics, which is focused on novel anti-fibrotic therapies, today announced the acquisition of ATXCo Inc, including its core asset, PAT-409, a Phase I-ready autotaxin inhibitor for patients with fibrotic diseases. 26 September 2019
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze